AMB303 / Aimed Bio - LARVOL DELTA

AMB303: A novel topo I payload ADC showing efficacy in NSCLC and TNBC, with potential for immune checkpoint combination therapy (AACR 2025) - "AMB303, an ADC conjugated with a novel Topo I inhibitor, is a potent therapeutic designed to target both primary tumor cells and recurrence or relapsed cancer tissues. When combined with immune checkpoint inhibitors, AMB303 demonstrated enhanced therapeutic efficacy, presenting a promising strategy to overcome immune resistance and improve treatment outcomes in cancer therapy."

Clinical • Combination therapy • IO biomarker • Breast Cancer • Colon Cancer • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ROR1